sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
tacggttaagttaaataagagtt | 1751 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Vinyl-phosphonate 2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"inf... |
tacggttaagttaaataagagtt | 1213 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tacggttaagttaaataagagtt | 1213 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tacggttaagttaaataagagtt | 1213 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tacggttaagttaaataagagtt | 1213 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tacggttaagttaaataagagtt | 1751 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tacggttaagttaaataagagtt | 1751 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atcaggaaggctgaaagtagatc | 6471 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atcaggaaggctgaaagtagatc | 6471 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atcaggaaggctgaaagtagatc | 6017 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]}],"locations":["2->2"],"infos":["OTHER"]},{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]}],"locations":["12->12"],"infos":["OTHER"]}] |
atcaggaaggctgaaagtagatc | 6017 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]}],"locations":["2->2"],"infos":["OTHER"]},{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]}],"locations":["12->12"],"infos":["OTHER"]}] |
atcaggaaggctgaaagtagatc | 6017 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atcaggaaggctgaaagtagatc | 6017 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atcaggaaggctgaaagtagatc | 6471 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atcaggaaggctgaaagtagatc | 6471 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
acctgctggaccatctatctgct | 6427 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]}],"locations":["7->7"],"infos":["OTHER"]}] |
acctgctggaccatctatctgct | 6427 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]}],"locations":["7->7"],"infos":["OTHER"]}] |
acctgctggaccatctatctgct | 6427 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
acctgctggaccatctatctgct | 6427 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ttagtgctggtgtaggtcttctg | 2900 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Vinyl-phosphonate 2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"inf... |
ttagtgctggtgtaggtcttctg | 2900 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Vinyl-phosphonate 2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"inf... |
ttagtgctggtgtaggtcttctg | 2900 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ttagtgctggtgtaggtcttctg | 2900 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ttagtgctggtgtaggtcttctg | 2630 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ttagtgctggtgtaggtcttctg | 2630 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ttagtgctggtgtaggtcttctg | 2630 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ttagtgctggtgtaggtcttctg | 2630 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
gcttgaggatcttccgatggt | 6750 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gcttgaggatcttccgatggt | 6750 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gcttgaggatcttccgatggt | 5683 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
gcttgaggatcttccgatggt | 5683 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
gcttgaggatcttccgatggt | 5683 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
gcttgaggatcttccgatggt | 5683 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
gcttgaggatcttccgatggt | 6750 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
gcttgaggatcttccgatggt | 6750 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tctgagtgagtaaattattttag | 1137 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tctgagtgagtaaattattttag | 1137 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tctgagtgagtaaattattttag | 1675 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tctgagtgagtaaattattttag | 1675 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tctgagtgagtaaattattttag | 1137 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tctgagtgagtaaattattttag | 1137 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tctgagtgagtaaattattttag | 1675 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Vinyl-phosphonate 2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"inf... |
tctgagtgagtaaattattttag | 1675 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Vinyl-phosphonate 2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"inf... |
taatgagcattaatgttttctga | 2011 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
taatgagcattaatgttttctga | 2011 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
taatgagcattaatgttttctga | 2011 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
taatgagcattaatgttttctga | 2011 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tagcatcatcaggatgaggctga | 2612 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tagcatcatcaggatgaggctga | 2612 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tagcatcatcaggatgaggctga | 2882 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tagcatcatcaggatgaggctga | 2882 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tagcatcatcaggatgaggctga | 2882 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Vinyl-phosphonate 2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"inf... |
tagcatcatcaggatgaggctga | 2882 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Vinyl-phosphonate 2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"inf... |
tagcatcatcaggatgaggctga | 2612 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tagcatcatcaggatgaggctga | 2612 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ggcatgcctggtattgctgct | 4892 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ggcatgcctggtattgctgct | 4892 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ggcatgcctggtattgctgct | 5162 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
ggcatgcctggtattgctgct | 5162 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
ggcatgcctggtattgctgct | 4892 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ggcatgcctggtattgctgct | 4892 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ggcatgcctggtattgctgct | 5162 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
ggcatgcctggtattgctgct | 5162 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atgggcactttcttgtctgat | 7002 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atgggcactttcttgtctgat | 7002 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atgggcactttcttgtctgat | 5912 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atgggcactttcttgtctgat | 5912 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atgggcactttcttgtctgat | 5912 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atgggcactttcttgtctgat | 5912 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atgggcactttcttgtctgat | 7002 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
atgggcactttcttgtctgat | 7002 | IL309897A | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
gaggaccagacagacacggaa | 2793 | IL309897A0 | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gaggaccagacagacacggaa | 2793 | IL309897A0 | הרכבי IRNA גן מטרה הקשור להפרעה מטבולית ושיטות לשימוש בהם | 20,240,201 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gaggaccagacagacacggaa | 3198 | IL309897A | Metabolic disorder-associated target gene irna compositions and methods of use thereof | 20,240,301 | 101 | [
"CN",
"IN",
"US",
"WO",
"JP",
"NZ",
"CL",
"EP",
"RU",
"HK",
"IL",
"SG",
"CA",
"TW",
"CO",
"ZA",
"SA",
"AU",
"MX",
"AR",
"BR",
"KR"
] | null |
tatgtcttgacaaactgtcattc | 809 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyluridine-3'-phosphorothioate 5'-(E)-Vinylphosphonate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"... |
tatgtcttgacaaactgtcattc | 809 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyluridine-3'-phosphorothioate 5'-(E)-Vinylphosphonate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"... |
tatgtcttgacaaactgtcattc | 539 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatgtcttgacaaactgtcattc | 539 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatgtcttgacaaactgtcattc | 539 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatctttctccagaagttttacg | 5239 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatctttctccagaagttttacg | 5239 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatctttctccagaagttttacg | 5239 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatctttctccagaagttttacg | 6103 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatctttctccagaagttttacg | 6103 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tatctttctccagaagttttacg | 6103 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggttgggttcatctgagcaagag | 3030 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggttgggttcatctgagcaagag | 3030 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggttgggttcatctgagcaagag | 3030 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggttgggttcatctgagcaagag | 2381 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggttgggttcatctgagcaagag | 2381 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggttgggttcatctgagcaagag | 2381 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
attgaaggccgagttggcgtagc | 1489 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
attgaaggccgagttggcgtagc | 1489 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
attgaaggccgagttggcgtagc | 1489 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
attgaaggccgagttggcgtagc | 1219 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
attgaaggccgagttggcgtagc | 1219 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
attgaaggccgagttggcgtagc | 1219 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
aagcgccatcagcagacccatgc | 1446 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
aagcgccatcagcagacccatgc | 1446 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
aagcgccatcagcagacccatgc | 1446 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.